Itraconazole interactions: what patients need to know

Last reviewed: April 2026

Key points

  • Itraconazole can interact with many other medicines.
  • It usually does this by affecting liver enzymes, especially CYP3A4.
  • Some combinations need careful monitoring, while others are best avoided.
  • Capsules and liquid formulations are not handled by the body in exactly the same way.
  • This page highlights the interactions most likely to matter to people with aspergillosis.

What is itraconazole?

Itraconazole is an azole antifungal used in aspergillosis and other fungal infections. It has a relatively high interaction burden, so medicine checks are especially important before starting it and whenever another medicine is added, stopped, or changed.

Why itraconazole interacts with so many medicines

Itraconazole can increase the levels of some other medicines by affecting liver enzymes, especially CYP3A4. This means that some medicines may become stronger than intended, which can increase the risk of side effects or toxicity.

The interaction groups most likely to matter

Steroids and inhalers

This is one of the most important groups for many aspergillosis patients, especially those with asthma or allergic bronchopulmonary aspergillosis. Itraconazole can increase exposure to some steroids, including inhaled steroids, which may increase the risk of steroid side effects.

Possible symptoms to report: unusual weight gain, easy bruising, increased facial rounding, mood changes, worsening blood sugar control, weakness, or marked fatigue.

Statins

Some statins can become much stronger when taken with itraconazole. This can increase the risk of muscle toxicity.

Possible symptoms to report: new muscle pain, muscle weakness, or dark urine.

Blood thinners

Itraconazole can increase the effect of some blood thinners, which may raise bleeding risk.

Possible symptoms to report: unusual bruising, bleeding that is hard to stop, black stools, vomiting blood, or coughing up much more blood than usual.

Heart and rhythm medicines

Some combinations can increase the risk of serious heart rhythm problems. Itraconazole is also used cautiously in people with a history of ventricular dysfunction or heart failure unless the infection is serious.

Possible symptoms to report: fainting, palpitations, marked dizziness, increasing ankle swelling, or worsening breathlessness.

Sleeping tablets, sedatives, and some mental health medicines

Some sedatives and psychotropic medicines can become stronger when combined with itraconazole, increasing the risk of drowsiness, confusion, falls, or breathing problems.

Immunosuppressants

Medicines such as tacrolimus and ciclosporin can rise significantly when taken with itraconazole and usually need specialist monitoring.

Medicines that can make itraconazole less effective

Some medicines lower itraconazole levels, which means the antifungal may not work as well. This can happen with some anti-seizure medicines, rifampicin-type antibiotics, and some antiviral medicines.

Acid-reducing medicines and itraconazole capsules

Reduced stomach acid can lower the absorption of itraconazole capsules. This means reflux medicines, antacids, and some acid-suppressing treatments can affect how well the capsules work. The liquid formulation behaves differently and should not be treated as interchangeable with capsules.

What patients should do in practice

  • Keep a current medicines list and bring it to appointments.
  • Tell clinicians and pharmacists if you are taking itraconazole.
  • Ask specifically about inhalers, steroid tablets, statins, blood thinners, and reflux treatment.
  • Do not change doses or stop medicines without advice.
  • If your itraconazole formulation changes, ask whether it should be taken with food or on an empty stomach.

When to seek medical advice

Seek urgent medical advice for severe bleeding, black stools, vomiting blood, severe muscle pain, fainting, marked palpitations, or rapidly worsening breathlessness.

Important

This page is not a full interaction database. For a complete medicine-by-medicine check, use the BNF interaction checker or speak to a pharmacist or clinician.

References


Amphotericin B interactions: what patients need to know

Last reviewed: April 2026

Key points

  • Amphotericin B comes in different formulations, and they are not interchangeable.
  • Its main interaction risks are different from the azoles.
  • The most important problems are usually kidney stress, low potassium, low magnesium, and additive toxicity with other medicines.
  • These risks matter most with intravenous treatment.
  • If you hear “amphotericin B”, it is important to know which formulation is being used.

What is amphotericin B?

Amphotericin B is an antifungal used mainly for serious fungal infections. In modern UK practice this often means liposomal amphotericin B, but conventional amphotericin B deoxycholate is also a recognised formulation.

Why amphotericin B interactions are different from azoles

Unlike azole antifungals, amphotericin B does not mainly cause medicine interactions through liver enzymes. Its most important interaction risks usually relate to kidney injury, low potassium, low magnesium, and infusion-related effects.

The interaction groups most likely to matter

Other medicines that can damage the kidneys

This is one of the most important groups. Combining amphotericin B with other nephrotoxic medicines can increase the risk of kidney injury.

Diuretics, steroids, and other medicines that lower potassium

Amphotericin B can lower potassium, and some other medicines can make this worse. This may increase the risk of weakness, cramps, or heart rhythm problems.

Digoxin and heart-rhythm-sensitive situations

Low potassium caused by amphotericin B can make digoxin-related toxicity more likely and may increase the importance of electrolyte monitoring.

Flucytosine

When combined with flucytosine, specialist monitoring may be needed because toxicity can increase.

Some cancer medicines and intensive hospital treatments

In hospital, additive toxicity with other intensive treatments may be particularly important, especially where kidneys and electrolytes are already under strain.

White blood cell transfusions

Acute lung reactions are a recognised specialist concern if amphotericin B is given during or soon after leukocyte transfusions.

Why the formulations matter

Amphotericin B formulations are not interchangeable. Conventional amphotericin B deoxycholate and liposomal amphotericin B have different dosing, different handling by the body, and different safety profiles. Using the wrong formulation in the wrong dose has caused serious and even fatal errors.

In general, liposomal amphotericin B is less nephrotoxic than conventional amphotericin B deoxycholate, but it still requires careful monitoring.

What patients should do in practice

  • Ask which amphotericin B formulation is being used.
  • Tell the clinical team about all medicines, especially kidney-risk medicines, diuretics, steroids, and digoxin.
  • Expect blood tests to monitor kidney function, potassium, and magnesium during intravenous treatment.
  • Report weakness, reduced urine output, worsening swelling, palpitations, or marked dizziness.

When to seek medical advice

Seek urgent medical help for severe breathlessness, fainting, major palpitations, or a rapid deterioration during treatment.

Important

This page is educational and does not list every possible interaction. Amphotericin B treatment is usually managed by specialist teams, especially when given intravenously.

References


Isavuconazole interactions: what patients need to know

Last reviewed: April 2026

Key points

  • Isavuconazole can interact with other medicines, but its interaction profile is often less complex than older azoles.
  • It mainly interacts through CYP3A4.
  • Some medicines can increase isavuconazole levels, while others can reduce its effectiveness.
  • It has an important difference from some other azoles: it can shorten the QT interval.
  • It is still essential to check new medicines carefully.

What is isavuconazole?

Isavuconazole is a newer azole antifungal used in invasive aspergillosis and some other serious fungal infections. It is often seen as having a more predictable interaction profile than some older azoles, but it still has important interactions.

Why isavuconazole interacts with other medicines

Isavuconazole is mainly linked to CYP3A4. This means some medicines can become stronger when combined with it, while other medicines can lower isavuconazole levels and reduce its effectiveness.

The interaction groups most likely to matter

Medicines that reduce isavuconazole effectiveness

Some medicines, including rifampicin-type antibiotics and certain anti-seizure drugs, can lower isavuconazole levels and may make treatment ineffective.

Steroids

Some steroid levels may rise with isavuconazole, although the interaction pattern is often less intense than with some older azoles.

Immunosuppressants

Medicines such as tacrolimus and ciclosporin may increase and usually need specialist review and monitoring.

Blood thinners

Some blood thinners may become stronger, increasing bleeding risk.

Statins

Some statin levels may increase, which can raise the risk of muscle side effects.

Important isavuconazole-specific points

QT shortening

Unlike several other azole antifungals, isavuconazole can shorten the QT interval. This is an important difference and should be considered when other heart medicines are being reviewed.

Generally simpler interaction profile

Compared with itraconazole and voriconazole, isavuconazole is often considered a little easier to manage in patients taking several medicines, although checks are still essential.

What patients should do in practice

  • Tell your pharmacist or clinician if you are taking isavuconazole.
  • Check before starting prescription, over-the-counter, or herbal medicines.
  • Ask specifically about anti-seizure drugs, antibiotics, blood thinners, and heart medicines.
  • Do not stop or change medicines without advice.

When to seek medical advice

Seek medical advice urgently for severe bleeding, fainting, severe palpitations, severe muscle pain, or rapid worsening after a medicine change.

Important

This page is educational and not a complete interaction database. For a full check, use the BNF interaction checker or speak to a pharmacist or clinician.

References


Posaconazole interactions: what patients need to know

Last reviewed: April 2026

Key points

  • Posaconazole can interact with other medicines, although its interaction pattern is often a little simpler than itraconazole or voriconazole.
  • It mainly interacts through CYP3A4 inhibition.
  • Important interaction groups include immunosuppressants, steroids, blood thinners, and some heart medicines.
  • Some medicines can reduce posaconazole levels and make treatment less effective.
  • Tablets and oral suspension are not interchangeable in the same way.

What is posaconazole?

Posaconazole is an azole antifungal used in aspergillosis and in some high-risk patients for prevention of fungal infection. It is often seen as somewhat easier to manage than some older azoles, but important interactions still exist.

Why posaconazole interacts with other medicines

Posaconazole mainly affects CYP3A4, a key liver enzyme involved in handling many medicines. This means some drugs can become stronger, while some combinations can lower posaconazole levels and make it less effective.

The interaction groups most likely to matter

Steroids

Posaconazole can increase exposure to some steroids, including inhaled or oral steroids, which may increase the risk of steroid side effects.

Immunosuppressants

Medicines such as tacrolimus and ciclosporin can rise significantly with posaconazole and usually need close specialist monitoring.

Blood thinners

Some blood thinners may become stronger, increasing bleeding risk.

Statins

Some statins can rise in level, increasing the risk of muscle problems.

Heart rhythm medicines

Some combinations can increase the risk of heart rhythm problems and need careful review.

Medicines that reduce posaconazole effectiveness

Some medicines, including rifampicin-type antibiotics and certain anti-seizure drugs, can lower posaconazole levels and may make treatment less effective.

Posaconazole formulations and absorption

Posaconazole comes in different forms, including tablets, oral suspension, and infusion. The oral suspension and tablets are not handled identically by the body and should not be assumed to be interchangeable dose-for-dose without clinical advice.

In practice, the tablets tend to be more predictable than the suspension.

What patients should do in practice

  • Tell your pharmacist or clinician if you are taking posaconazole.
  • Ask about new medicines, especially blood thinners, steroids, statins, and heart medicines.
  • If your formulation changes, ask whether there are any special instructions.
  • Do not stop or swap medicines without advice.

When to seek medical advice

Seek medical advice urgently for severe bleeding, fainting, major palpitations, severe muscle pain, or rapid worsening after a medicine change.

Important

This page does not list every interaction. For a full check, use the BNF interaction checker or speak to a pharmacist or clinician.

References


Antifungal drug interactions: what patients with aspergillosis need to know

Last reviewed: April 2026

Key points

  • Antifungal medicines can interact with other medicines, including inhalers, steroid tablets, blood thinners, heart medicines, cholesterol tablets, and some over-the-counter or herbal products.
  • The azole antifungals usually interact by affecting how the liver handles medicines.
  • Amphotericin B is different: its main interaction risks are more often linked to kidneys, potassium, magnesium, and infusion-related effects.
  • This page gives an overview. It does not list every interaction.
  • For a full medicine-by-medicine check, use the BNF interaction checker or ask a pharmacist or clinician.

Why interactions matter in aspergillosis

People with aspergillosis often take more than one medicine. This may include inhalers, steroid tablets, medicines for reflux, antibiotics, pain relief, blood pressure treatment, blood thinners, cholesterol tablets, and drugs for other long-term conditions. That means medicine checks are especially important whenever an antifungal is started, stopped, or changed.

How the main antifungals differ

Most long-term interaction questions in aspergillosis involve the azole antifungals: itraconazole, voriconazole, posaconazole, and isavuconazole. These mainly interact because they affect liver enzymes, especially CYP3A4, although some also affect CYP2C9 and CYP2C19.

Amphotericin B behaves differently. Its most important risks are usually kidney stress, low potassium, low magnesium, and additive toxicity with other medicines rather than classic liver-enzyme interactions.

Quick comparison table

Antifungal Main interaction pattern Typical complexity Important extra point
Itraconazole Strong enzyme-based interactions, especially CYP3A4 High Capsules and liquid are not handled by the body in the same way
Voriconazole Complex enzyme-based interactions involving several CYP pathways High More variable between patients; visual side effects and photosensitivity are well recognised
Posaconazole Mainly CYP3A4-related interactions Moderate Tablets and oral suspension are not interchangeable in the same way
Isavuconazole Mainly CYP3A4-related interactions, usually less complex than older azoles Lower to moderate Can shorten the QT interval
Amphotericin B Kidney, potassium, magnesium, and infusion-related interaction risks Different rather than simpler Formulations are not interchangeable

Individual antifungal guides

What patients should do in practice

  • Keep an up-to-date list of all medicines, including inhalers, creams, over-the-counter medicines, supplements, and herbal products.
  • Tell your doctor, nurse, pharmacist, or hospital team that you are taking an antifungal.
  • Do not start, stop, or swap medicines on your own because of something you have read online.
  • Ask specifically about new medicines, steroid changes, reflux treatment, blood thinners, cholesterol medicines, and heart medicines.

When to seek medical advice

Seek medical advice promptly if symptoms change after a medicine is started, stopped, or changed. Seek urgent help for severe bleeding, fainting, severe muscle pain, marked palpitations, rapidly worsening breathlessness, severe drowsiness, or a sudden significant decline in your health.

Important

This resource is educational. It does not replace personalised advice from your clinical team, GP, or pharmacist, and it is not a complete interaction database.

References


Why Headaches Can Occur in Aspergillosis

Last reviewed: March 2026

Key Points

  • Headaches are relatively common in people living with aspergillosis, but they usually have multiple contributing causes.
  • Common causes include sinus involvement, inflammation, sleep disturbance, and medication effects.
  • Antifungal medicines such as itraconazole may improve some symptoms indirectly but can also occasionally cause headaches.
  • Patterns (timing, location, triggers) can help identify likely causes, but headaches are rarely due to one factor alone.
  • New, severe, or unusual headaches should always be assessed by a healthcare professional.

Table of Contents

Overview

Many people living with aspergillosis report headaches at some point during their illness. These headaches can vary in type, severity, and timing, and may be confusing—especially when they change over time or seem linked to treatment.

In most cases, headaches are not caused by a single factor. Instead, they reflect a combination of:

  • local effects (such as sinus pressure)
  • immune system activity
  • medication effects
  • sleep and general health factors

Understanding these different contributors can help make sense of symptoms and support more informed discussions with your clinical team.

Sinus involvement (common cause)

When Aspergillus affects the sinuses (sometimes called fungal sinusitis), this can directly cause headaches.

This happens because:

  • sinus drainage becomes blocked
  • pressure builds up in the sinus cavities
  • the lining of the sinuses becomes inflamed

Typical features:

  • pain or pressure in the forehead, cheeks, or behind the eyes
  • worsening when bending forward
  • a feeling of fullness or congestion

This is one of the most direct ways aspergillosis can lead to headaches.

Inflammation and immune response

Even when the sinuses are not directly involved, the body’s immune response to fungal material can cause systemic effects.

The immune system releases signalling molecules (such as cytokines) that can:

  • increase inflammation
  • affect blood vessels
  • trigger headache pathways

This type of headache can feel similar to a “flu-like” or inflammatory headache.

Allergic-type responses (e.g. ABPA)

In conditions such as Allergic Bronchopulmonary Aspergillosis (ABPA), the immune system reacts strongly to Aspergillus.

This may involve:

  • allergic pathways
  • histamine and related mediators
  • ongoing airway inflammation

Possible symptoms:

  • head pressure or discomfort
  • fluctuating headaches
  • a “foggy” or unwell feeling

These headaches are often less clearly localised than sinus-related pain.

Medication effects

Some treatments used in aspergillosis can contribute to headaches.

Antifungal medications (e.g. itraconazole):

  • headache is a recognised side effect in some people
  • effects vary between individuals

Steroids (if prescribed):

  • can affect sleep and mood
  • may influence blood pressure
  • can indirectly contribute to headaches

Medication effects can sometimes overlap with disease-related symptoms, making patterns harder to interpret.

Sleep disturbance and night symptoms

Sleep disruption is common in chronic lung conditions.

Possible contributors include:

  • night-time coughing
  • breathlessness
  • discomfort or anxiety

Poor sleep can lead to:

  • morning headaches
  • increased sensitivity to pain
  • fatigue-related headaches

Breathing and oxygen levels

In some people with more advanced lung involvement:

  • oxygen levels may be slightly reduced
  • breathing effort may increase

This can contribute to:

  • morning headaches
  • fatigue and cognitive symptoms

Not all patients experience this, but it is an important factor in some cases.

General health factors

Headaches can also be influenced by general aspects of living with a long-term condition:

  • dehydration
  • fatigue
  • reduced activity levels
  • stress or anxiety

These factors can contribute to tension-type headaches or make other headache types more noticeable.

Understanding headache patterns

Looking at patterns can sometimes help identify likely contributors.

  • Facial pressure worse on bending: may suggest sinus involvement
  • Early morning headaches: may relate to sleep or breathing patterns
  • Fluctuating or “wave-like” symptoms: may reflect inflammation or immune activity
  • New headaches after starting medication: may be treatment-related

However, these are general observations only and do not replace clinical assessment.

Headaches in Aspergillosis: Interactive Decision Aid

This tool helps patients and carers think about common patterns that can contribute to headaches in aspergillosis. It does not diagnose the cause of a headache.

It is designed to support discussion with a healthcare professional and highlight possible contributors such as sinus involvement, inflammation, medication effects, sleep disturbance, and breathing-related factors.

Important: This tool is for general information only. It cannot determine the cause of an individual’s symptoms and does not replace medical advice. If you are concerned about headaches or changes in symptoms, please speak to your healthcare team.

1. Where is the pain mainly felt?



2. When is it most noticeable?



3. What does it feel like?



4. What other features are present?






5. Are there any red flags?



Possible contributors

This panel highlights common patterns only. It is not a diagnosis and does not replace medical assessment.

These are possible patterns only and are not a diagnosis.
This tool is intended to support discussion and reflection. If your headaches are new, worsening, or concerning, speak to your healthcare team.
Select your answers and click Show possible contributors.

Common questions

Are headaches a recognised symptom of aspergillosis?

They can occur, but are usually indirect and caused by associated factors such as sinus disease or inflammation.

Can antifungal treatment improve headaches?

In some cases, yes—if symptoms are linked to fungal-related inflammation. However, antifungals can also occasionally cause headaches as a side effect.

Are “histamine-type” headaches part of aspergillosis?

Some patients describe symptoms in this way, but the underlying mechanism is often more complex than histamine alone.

Why do my headaches change over time?

This is common and may reflect changes in inflammation, treatment, sleep, or overall health.

When to seek medical advice

You should seek medical advice if you experience:

  • new or unusually severe headaches
  • headaches that are worsening over time
  • neurological symptoms (e.g. vision changes, weakness, confusion)
  • fever, neck stiffness, or other concerning symptoms

If you are unsure whether your headaches are related to aspergillosis, treatment, or another cause, it is important to discuss this with your healthcare team.

Summary

Headaches in people with aspergillosis are usually caused by a combination of factors rather than a single issue.

The most common contributors include:

  • sinus involvement
  • immune and inflammatory responses
  • sleep disturbance
  • medication effects

Understanding patterns and changes over time can be helpful, but medical assessment is important if symptoms are new, severe, or concerning.

Author and review

Prepared for: aspergillosis.org

Audience: Patients and non-specialist readers

Important: This article is for general information only and does not replace individual medical advice.

References

  1. Patterson TF et al. (2016). Practice Guidelines for the Diagnosis and Management of Aspergillosis.
    PMID: 27365388
  2. Denning DW et al. (2016). Chronic pulmonary aspergillosis guidelines.
    PMID: 26699723
  3. Chakrabarti A et al. (2009). Fungal sinusitis: a categorization and definitional schema.
    PMID: 19522756

Why Diagnosis Can Take Time — and Why You Are Not Alone

Last reviewed: 18 March 2026

Who this page is for: Patients and carers who have been living with symptoms for some time without a clear diagnosis, including those eventually diagnosed with aspergillosis.

Key points

  • Long diagnostic journeys are common in many chronic and rare conditions—not just aspergillosis.
  • Delays do not mean your symptoms were not real or important.
  • Diagnosis often becomes clear over time, as patterns develop.
  • Many patients go through similar experiences before reaching answers.
  • Specialist centres play an important role when conditions are complex.

You are not alone in this

One of the most important things to understand is this:

Long and difficult diagnostic journeys are common—especially in chronic or complex illness.

Many people living with conditions such as chronic pulmonary aspergillosis (CPA) or allergic bronchopulmonary aspergillosis (ABPA) describe months or years of symptoms before a clear diagnosis was made.

This experience, while frustrating, is not unusual—and it does not mean your care has failed.

This happens in many conditions

Aspergillosis is not unique in this respect.

Similar diagnostic journeys are seen in:

  • chronic lung diseases
  • autoimmune conditions
  • rare infections
  • conditions with overlapping symptoms (e.g. fatigue syndromes)

In all of these, the same pattern often occurs:

  • early symptoms are non-specific
  • common conditions are treated first
  • tests may initially be normal
  • the true pattern only becomes clear over time

Why time helps diagnosis

Many conditions only become recognisable as patterns develop over time.

Although it can feel like delay, time often provides essential information.

Patterns emerge

  • symptoms become more consistent
  • flare-ups follow recognisable triggers
  • response to treatment becomes clearer

Tests become more informative

  • changes appear on imaging (e.g. CT scans)
  • blood markers become more clearly abnormal
  • microbiology results become more consistent

What was unclear early on can become much more visible later.

The turning point

Many patients describe a moment when things begin to change:

  • symptoms no longer fit common conditions
  • treatments stop working as expected
  • a clinician recognises a pattern

This is often the point where less common diagnoses—including aspergillosis—are considered.

The role of specialist centres

Complex conditions are often best diagnosed in specialist centres with experience in that field.

In the UK, the National Aspergillosis Centre provides:

  • expert multidisciplinary assessment
  • access to specialist diagnostics
  • experience in recognising patterns of disease

Referral to a specialist centre is often a key step in reaching a diagnosis.

The emotional impact

Long periods without answers can be deeply challenging.

Patients often describe:

  • frustration and uncertainty
  • feeling unheard or misunderstood
  • loss of confidence in their own body

These reactions are entirely understandable.

Your experience is valid—even if the diagnosis took time to emerge.

Moving forward

Once a diagnosis is made, many patients feel a sense of relief—even if treatment is still needed.

A diagnosis provides:

  • an explanation for symptoms
  • a direction for treatment
  • a clearer future plan

Even before diagnosis, it is important to remember:

You are still on a pathway—just not always a straight one.

Common questions

Does a long delay mean something was missed?

Not necessarily. Many conditions are only diagnosable once they have developed further.

Should I have been referred earlier?

Sometimes earlier referral is helpful, but it usually depends on how symptoms evolve over time.

Is this unique to aspergillosis?

No—this pattern is seen across many chronic and rare conditions.


Why Aspergillosis Is So Hard to Diagnose


Last reviewed: 18 March 2026
Who this page is for: Patients, carers, general practitioners, respiratory clinicians, specialist nurses, and anyone trying to understand why the road to diagnosis can be long and confusing.

Key points

  • Aspergillosis is often difficult to diagnose because its symptoms can look very similar to those of more common conditions.
  • Diagnosis usually depends on several pieces of evidence being brought together, rather than one simple test.
  • Doctors are trained to consider common conditions first, because this is usually the safest and most efficient approach.
  • This approach works well for many patients, but it can delay recognition of conditions such as aspergillosis.
  • Delays are often caused by the way healthcare systems are organised, not by lack of care or effort from individual clinicians.
  • Patients can help by keeping a clear record of symptoms, tests, treatments, and how things have changed over time.
Many people with aspergillosis say that one of the hardest parts of their illness was not just the symptoms, but the long and uncertain path to getting an answer. Some were treated several times for asthma flare-ups, chest infections, or chronic obstructive pulmonary disease (COPD) before fungal disease was seriously considered.This can be frightening and frustrating. It is natural to ask: Why did it take so long?The answer is usually not that nobody was trying. More often, it is because aspergillosis does not fit neatly into the way modern medicine is designed to recognise disease.

Why diagnosis can be difficult

Aspergillosis is not a single illness but a group of conditions caused by Aspergillus, a mould commonly found in the environment. These include:

Diagnosis usually depends on combining:

  • symptoms over time
  • CT scan findings
  • blood tests (including immunological tests)
  • sputum microbiology
  • clinical history

There is rarely a single “yes or no” test, which is why diagnosis can take time.

What the patient journey often looks like

Early symptoms

Symptoms such as cough, breathlessness, fatigue, or sputum are common across many conditions including bronchiectasis, asthma, and infection.

Treatment for common conditions

Initial treatment often includes antibiotics, inhalers, or steroids. These are appropriate first steps based on clinical guidelines such as those from the British Thoracic Society (BTS).

Ongoing symptoms

When symptoms persist or return, further investigation is usually needed.

The turning point

At some stage, fungal disease may be considered and tests for Aspergillus are performed.

Why doctors tackle common conditions first

Why do doctors start with common conditions?

Doctors treat common diseases first, prioritizing efficiency, patient safety, and high-probability outcomes. This approach, considering the most likely diagnosis first, helps manage patient health efficiently and effecctively before investigating rare or complex conditions.

This approach is safe and effective for most people, but conditions like aspergillosis can sit outside these usual pathways.

Where delays can happen

Overlap of symptoms

Symptoms overlap with many conditions, including tuberculosis and lung cancer.

No single definitive test

Diagnosis often requires combining multiple test results rather than relying on one.

Gradual disease progression

Conditions such as CPA may evolve over months or years.

Multiple conditions

Patients may have more than one lung condition at the same time.

Why this is often about the system, not the individual doctor

Healthcare systems are designed to manage large numbers of patients efficiently and safely. This means prioritising common conditions first.

However, aspergillosis often requires specialist input. In the UK, this may include referral to the National Aspergillosis Centre, which provides expert assessment and management.

International guidance from organisations such as ESCMID (European Society of Clinical Microbiology and Infectious Diseases) also highlights the complexity of fungal diseases.

What patients can do

  • Keep a record of symptoms and treatments
  • Ask when diagnosis should be reviewed
  • Discuss whether further tests are needed
  • Use trusted information sources such as our diagnosis guide

A more balanced way to think about delay

Diagnosis is often not a single event but a process that unfolds over time.

The goal is to recognise patterns earlier and ensure patients who need specialist input are identified sooner.

Common questions

Why was I treated for other conditions first?

Because those conditions are more common and more likely.

Should I ask about aspergillosis?

Yes, especially if symptoms are persistent or unusual—but it should be part of a broader discussion.

When to seek medical advice

  • Persistent or worsening symptoms
  • Coughing up blood
  • Unexplained weight loss

References and further reading


Nontuberculous Mycobacteria (NTM–MAC) and Aspergillosis

Why these infections sometimes occur together

Audience: Aspergillosis patients, carers, GPs and non-specialist clinicians

Some patients with Allergic Bronchopulmonary Aspergillosis (ABPA) may be investigated for nontuberculous mycobacteria (NTM), because airway damage from ABPA can increase susceptibility to other lung infections.


Key points

  • Nontuberculous mycobacteria (NTM) are environmental bacteria that sometimes infect damaged lungs.
  • The most common NTM causing lung disease is the Mycobacterium avium complex (MAC).
  • NTM infection and aspergillosis often occur in the same patients because both thrive in damaged airways such as bronchiectasis or lung cavities.
  • Some patients with ABPA are investigated for NTM because ABPA can lead to bronchiectasis and impaired mucus clearance.
  • NTM infections usually grow very slowly, so treatment is sometimes monitored rather than started immediately.
  • Treating NTM and aspergillosis together can be difficult because some NTM antibiotics interfere with antifungal medicines.
  • Doctors usually treat the infection causing the most harm first while monitoring the other carefully.

Table of contents

  1. What are NTM?
  2. What is Mycobacterium avium complex (MAC)?
  3. Why NTM infections occur in some people
  4. What is bronchiectasis?
  5. Why patients with ABPA may be asked about NTM
  6. Why NTM and Aspergillus infections often occur together
  7. The lung infection cycle
  8. Chronic lung disease as a microbial ecosystem
  9. Why treatment can be complicated
  10. When treatment for NTM may be delayed
  11. How doctors balance treatment decisions
  12. NTM vs Aspergillosis – comparison table
  13. Common questions patients ask about NTM and Aspergillus
  14. When should patients seek medical advice?
  15. Reducing exposure to NTM in the environment

What are nontuberculous mycobacteria (NTM)?

Nontuberculous mycobacteria (NTM) are bacteria found naturally in the environment.

They live in:

  • soil
  • water
  • dust
  • plumbing systems
  • shower heads and taps

Unlike tuberculosis, these bacteria are not normally spread between people.

Most people inhale them regularly without becoming ill. However, in some people with damaged lungs, these bacteria can establish a long-term lung infection.

Back to top

What is Mycobacterium avium complex (MAC)?

The Mycobacterium avium complex (MAC) is the most common cause of NTM lung disease.

This group includes:

  • Mycobacterium avium
  • Mycobacterium intracellulare

MAC lung disease usually develops slowly over months or years.

Symptoms may include:

  • chronic cough
  • sputum production
  • breathlessness
  • fatigue
  • weight loss

Because symptoms develop gradually, diagnosis can sometimes take time.

Back to top

Why NTM infections occur in some people

NTM infections usually develop in people who already have structural lung disease.

Examples include:

  • bronchiectasis
  • chronic obstructive pulmonary disease (COPD)
  • cystic fibrosis
  • previous tuberculosis
  • severe asthma
  • aspergillosis

In these conditions, the lungs have damaged or widened airways, making it harder to clear mucus and microbes.

Back to top

What is bronchiectasis?

Bronchiectasis is a condition where the airways become permanently widened and distorted.

In healthy lungs, mucus is cleared using:

  • mucus movement
  • tiny hair-like structures called cilia
  • coughing

In bronchiectasis:

  • mucus collects in the airways
  • microbes become trapped
  • infections become more likely

Bronchiectasis is common in patients with Allergic Bronchopulmonary Aspergillosis (ABPA) and other chronic lung diseases.

Back to top

Why patients with ABPA may be asked about NTM

Some patients with Allergic Bronchopulmonary Aspergillosis (ABPA) are surprised when their doctors start investigating nontuberculous mycobacteria (NTM).

This usually happens because ABPA can lead to bronchiectasis, which increases the risk of other lung infections.

In ABPA:

  • inflammation caused by allergic reactions to Aspergillus can damage the airways
  • over time the airways may become widened and distorted, causing bronchiectasis
  • mucus clearance becomes less effective

When mucus accumulates in the airways, microbes that are normally cleared from the lungs can sometimes persist. These may include:

  • nontuberculous mycobacteria (NTM)
  • Pseudomonas bacteria
  • other organisms that affect bronchiectasis patients

For this reason, doctors sometimes test patients with ABPA for NTM if:

  • CT scans show bronchiectasis or nodules
  • sputum cultures repeatedly grow unusual organisms
  • symptoms worsen without a clear explanation

Importantly, having ABPA does not mean you will develop NTM infection. Most patients with ABPA never develop NTM disease.

However, because the conditions share similar risk factors, doctors sometimes check for both.

Back to top

Why NTM and Aspergillus infections often occur together

NTM bacteria and Aspergillus fungi both thrive in damaged lungs.

Three factors explain the overlap.

1. Damaged airways trap microbes

When airways are widened or distorted:

  • mucus collects
  • microbes are not cleared effectively

This allows organisms such as NTM and Aspergillus to persist.

2. Chronic infection causes further lung damage

NTM infection can lead to:

  • inflammation
  • worsening bronchiectasis
  • lung nodules
  • sometimes lung cavities

These cavities can then be colonised by Aspergillus, which may lead to chronic pulmonary aspergillosis (CPA).

3. Aspergillus can worsen structural damage

Once Aspergillus becomes established it can cause:

  • inflammation
  • enlargement of lung cavities
  • worsening bronchiectasis

This further damage makes the lungs even more susceptible to infection.

Back to top

The lung infection cycle

In many patients the relationship between bronchiectasis, NTM and Aspergillus becomes a cycle:

  1. Lung disease develops
  2. Bronchiectasis forms
  3. NTM infection establishes
  4. Lung damage worsens
  5. Aspergillus colonises damaged tissue
  6. Chronic aspergillosis develops
  7. Lung damage continues

At this stage the lungs may contain multiple organisms simultaneously.

Back to top

Chronic lung disease as a microbial ecosystem

Doctors increasingly recognise that damaged lungs may contain several interacting microbes rather than a single infection.

Common organisms include:

  • Mycobacterium avium complex (MAC)
  • Aspergillus species
  • Pseudomonas bacteria
  • other organisms

For this reason clinicians sometimes describe chronic lung disease as a disturbed lung microbial ecosystem.

Back to top

Why treatment can be complicated

NTM and aspergillosis treatments can interact.

Typical MAC treatment includes:

  • azithromycin or clarithromycin
  • ethambutol
  • rifampicin

However rifampicin strongly reduces levels of antifungal drugs, including:

  • itraconazole
  • voriconazole
  • posaconazole

These antifungals are commonly used to treat chronic pulmonary aspergillosis.

Because of this interaction, treating both infections at the same time can be challenging.

Other medicines that may interact with rifampicin

Rifampicin affects how the liver processes many medicines. This means it can reduce the effectiveness of several commonly used drugs, including some treatments for heart conditions, blood thinners, hormonal medicines, and certain antidepressants.

Because of this, doctors and pharmacists always review a patient’s medication list before starting rifampicin. Patients should tell their healthcare team about all medicines they take, including over-the-counter medicines, inhalers, and herbal supplements. In most cases, safe alternatives or dose adjustments can be used if needed.

Back to top

When treatment for NTM may be delayed

Unlike many bacterial infections, MAC often progresses slowly.

Doctors sometimes monitor the infection before starting treatment. This approach is called active monitoring or watchful waiting.

Monitoring may include:

  • CT scans
  • sputum cultures
  • lung function tests
  • symptom assessment

Treatment may be delayed if:

  • symptoms are mild
  • CT scans are stable
  • another condition requires more urgent treatment

For example, aspergillosis may be treated first if it is causing the main symptoms or lung damage.

Back to top

How doctors balance treatment decisions

When both infections are present, clinicians try to identify which infection is currently causing the most harm.

Doctors consider:

Symptoms

  • worsening cough
  • breathlessness
  • fatigue
  • weight loss
  • haemoptysis (coughing blood)

CT scan findings

  • enlarging cavities
  • fungal balls
  • nodules typical of NTM disease
  • worsening bronchiectasis

Laboratory results

  • sputum cultures for NTM
  • Aspergillus blood tests, such as Aspergillus IgG

If one infection clearly explains the patient’s symptoms, that infection usually becomes the treatment priority.

Treatment plans may then change over time as the balance of disease changes.

Back to top

NTM vs Aspergillosis – What’s the difference?

Feature NTM (MAC) Lung Disease Aspergillosis
Type of organism Bacteria Fungus
Source Soil, water, plumbing Airborne fungal spores
Spread between people Rare Does not spread
Typical speed Slow, chronic infection Variable
Typical CT findings Nodules, bronchiectasis, cavities Cavities, fungal balls, airway inflammation
Treatment Long antibiotic courses, often 12–18 months Antifungal medicines
Drug interaction issues Rifampicin interferes with antifungals Antifungal levels can be reduced by rifampicin

Back to top

Common questions patients ask about NTM and Aspergillus

If MAC grows slowly, why treat it?

Although MAC grows slowly, it can still cause progressive lung damage over time.

Treatment is usually recommended if there is:

  • worsening symptoms
  • declining lung function
  • progressive CT scan changes

Can NTM be present without causing disease?

Yes. Some people have NTM colonisation without active infection.

Doctors diagnose NTM lung disease only when symptoms, imaging findings and repeated cultures all support the diagnosis.

Why do NTM and Aspergillus often occur together?

Both organisms tend to grow in damaged airways, especially where bronchiectasis is present and mucus clearance is poor.

Will both infections always be treated?

Not necessarily. Doctors often treat the infection causing the most immediate problem while monitoring the other.

Does NTM mean my aspergillosis is worsening?

Not necessarily. Both infections occur in damaged lungs, so they may simply share the same environment.

Can NTM lead to aspergillosis?

Sometimes. If NTM infection causes lung cavities or worsening bronchiectasis, these damaged areas may later become colonised by Aspergillus.

Should I worry if my doctor decides not to treat NTM immediately?

Not necessarily. Because MAC often progresses slowly, doctors sometimes choose active monitoring rather than immediate treatment.

Back to top

When should patients seek medical advice?

People living with aspergillosis, bronchiectasis or NTM infection often have ongoing symptoms such as cough and sputum production. These symptoms may fluctuate and do not always mean the disease is worsening.

However, certain changes should prompt medical review.

Seek medical advice if you notice worsening breathing symptoms

  • increasing breathlessness
  • a significant increase in cough
  • a noticeable increase in sputum production
  • sputum becoming thicker, darker or foul-smelling

These symptoms may indicate:

  • bacterial infection
  • worsening bronchiectasis
  • progression of NTM infection
  • worsening aspergillosis

Coughing up blood (haemoptysis)

Haemoptysis can occur in both bronchiectasis and aspergillosis.

Seek medical advice if:

  • bleeding increases
  • blood appears repeatedly
  • there is more than a small amount of blood
  • bleeding occurs suddenly with breathlessness

Large amounts of blood should be treated as a medical emergency.

Unexplained weight loss or increasing fatigue

Persistent or worsening:

  • weight loss
  • fatigue
  • loss of appetite

may indicate:

  • progressive infection
  • increasing inflammation
  • advancing NTM disease

Fever or feeling unwell

New symptoms such as:

  • fever
  • chills
  • chest discomfort
  • feeling generally unwell

may suggest a new infection, such as a bacterial chest infection, which may require treatment.

Rapid change in symptoms

Seek medical advice if you experience:

  • sudden worsening breathlessness
  • significant chest pain
  • new wheezing
  • severe fatigue developing quickly

Symptoms that may remain stable

Many people with chronic lung disease experience symptoms that remain relatively stable for long periods, including:

  • a chronic cough
  • daily sputum production
  • mild breathlessness
  • intermittent fatigue

Doctors monitor these symptoms over time using:

  • CT scans
  • sputum cultures
  • lung function tests

These investigations help clinicians determine whether infections such as NTM or Aspergillus are stable or progressing.

Back to top


Reducing exposure to NTM in the environment

Patients with bronchiectasis, ABPA, or other chronic lung diseases sometimes ask whether they should try to avoid environmental exposure to nontuberculous mycobacteria (NTM).

NTM are very common in the natural environment and cannot be completely avoided. They are found in:

  • soil and compost
  • garden dust
  • natural water sources
  • tap water and plumbing systems
  • showerheads
  • hot tubs and spa pools

For most people, the goal is sensible risk reduction rather than strict avoidance. Major lifestyle restrictions are usually not necessary.

Water exposure

NTM can grow in biofilms inside plumbing systems, including showerheads. Small amounts of bacteria may become airborne when water is aerosolised.

Some simple precautions may help reduce exposure:

  • avoid frequent use of hot tubs or spa pools
  • allow taps or showers to run briefly if they have not been used for several days
  • clean showerheads periodically to remove biofilm and limescale

Normal showering and bathing are considered safe for most patients.

NTM infection occurs when bacteria are inhaled into the lungs rather than swallowed. Drinking ordinary tap water is therefore considered safe for most people, and patients are not usually advised to avoid tap water for drinking.

Gardening and soil exposure

NTM bacteria are often present in soil and compost. Gardening can still be enjoyed safely with a few sensible precautions.

  • wear gloves when gardening
  • avoid inhaling dust from dry compost or soil
  • dampen compost before handling to reduce dust
  • wash hands after gardening

For people with bronchiectasis or NTM disease, wearing a mask during dusty gardening activities may help reduce inhalation of soil particles.

Reducing dust exposure

Activities that generate dust can increase inhalation of environmental microbes.

Helpful precautions include:

  • avoiding sweeping very dusty areas indoors
  • ventilating indoor spaces
  • wearing a mask during dusty tasks such as handling compost or dry soil

Cleaning showerheads

Cleaning showerheads periodically can help remove limescale and biofilms where microbes may grow.

A simple method is:

  1. Remove the showerhead if possible.
  2. Soak it in white vinegar for about 30–60 minutes.
  3. Gently scrub the spray holes with a small brush.
  4. Rinse thoroughly.
  5. Run hot water for 30–60 seconds before use.

If the showerhead cannot be removed, a plastic bag filled with vinegar can be tied around the head so that it soaks.

Cleaning every 1–3 months is usually sufficient.

What is usually not necessary

Experts generally do not recommend major lifestyle changes to avoid NTM exposure. In most cases it is not necessary to:

  • avoid showers
  • avoid gardening completely
  • install specialised water filtration systems

These activities are important for quality of life and general health, and evidence that strict avoidance prevents NTM disease is limited.

The most important protection

For patients with ABPA, bronchiectasis or aspergillosis, the most important protective measures remain:

  • good airway clearance
  • regular medical monitoring
  • prompt treatment of infections
  • maintaining overall lung health

Reducing environmental exposure may help slightly, but good management of lung disease remains the most important factor.

Back to top

Key message

When NTM and Aspergillus infections occur together, treatment decisions focus on which infection is currently causing the most damage, while avoiding harmful drug interactions.

For patients with ABPA, one reason NTM may be discussed is that ABPA can lead to bronchiectasis and impaired mucus clearance, which can make other infections more likely.

Many patients live with these conditions for years with careful monitoring and specialist management.


Author: National Aspergillosis Centre Patient Information Team
Last reviewed: March 2026


Travelling with Aspergillosis: A Comprehensive Guide to Safe and Stable Travel

This guide is for people living with:

  • Chronic Pulmonary Aspergillosis (CPA)
  • Allergic Bronchopulmonary Aspergillosis (ABPA)
  • Severe asthma (including fungal sensitisation)
  • Bronchiectasis
  • Fibrotic or structurally abnormal lung disease

Most people with stable disease can travel successfully. The goal is not restriction — it is risk reduction through preparation, environmental awareness, and early action if symptoms change.


Contents


1. Understanding Travel Risk in Aspergillosis

Travel risk arises from four domains:

  1. Structural lung vulnerability (cavities, fibrosis, bronchiectasis)
  2. Inflammatory instability (ABPA activity, asthma control)
  3. Environmental exposure (humidity, dust, pollution)
  4. Healthcare accessibility (if deterioration occurs)

Travel is usually safe when disease is stable and exposures are predictable.


2. Coordinating With Your Medical Team

Respiratory Clinic

  • Review recent imaging (particularly in CPA)
  • Assess haemoptysis history
  • Consider fit-to-fly testing if oxygen saturation borderline
  • Discuss standby rescue medication

GP

  • Ensure medication supply exceeds travel duration
  • Provide updated medication summary
  • Support vaccination review
  • Assist with insurance documentation

3. Assessing Stability Before Travel

Delay travel if within 4–6 weeks of:

  • Significant haemoptysis
  • Escalating breathlessness
  • Recent hospital admission
  • New antifungal initiation

Stable inflammatory markers and symptom plateau are reassuring.


4. Choosing a Destination: Environmental Determinants

Key determinants:

  • Humidity: promotes indoor mould growth
  • Flood history: water damage increases fungal load
  • Air pollution: triggers bronchospasm
  • Dust burden: irritates inflamed airways
  • Healthcare infrastructure: safety net if unwell

5. Regional Risk Patterns Explained

Lower Overall Respiratory Stress

  • Scandinavia
  • New Zealand
  • Canada (outside wildfire season)

Cooler climates limit mould growth; strong building codes reduce damp housing.

Moderate Risk

  • Mediterranean Europe

Generally safe when stable; monitor wildfire smoke and heat stress.

Higher Respiratory Stress

  • Tropical monsoon climates
  • Flood-prone regions
  • Highly polluted megacities
  • Dust storm zones

Humidity increases fungal proliferation; particulate pollution worsens airway inflammation.



6. Air Pollution & AQI Monitoring

Air pollution can exacerbate cough, bronchospasm, breathlessness and fatigue in people with chronic lung disease. In some urban environments, pollution may pose a greater day-to-day risk than fungal exposure.

The most widely used measure of air quality is the Air Quality Index (AQI), which combines several pollutants into a single score.


Key Pollutants That Matter in Lung Disease

  • PM2.5 – fine particulate matter small enough to penetrate deep into the lungs
  • PM10 – larger inhalable particles
  • Ozone (O₃) – irritates airways, especially in heat
  • Nitrogen dioxide (NO₂) – associated with traffic pollution

PM2.5 is particularly important in aspergillosis and severe asthma because it can:

  • Trigger airway inflammation
  • Increase mucus production
  • Worsen bronchospasm
  • Reduce exercise tolerance

Reliable Air Quality Monitoring Resources

These sites provide real-time data and forecasts:

  • World Air Quality Index (WAQI)
    https://waqi.info
    Interactive global map with live AQI data for cities worldwide.
  • IQAir (AirVisual)
    https://www.iqair.com
    Detailed pollutant breakdowns, 7-day forecasts and wildfire smoke tracking.
  • UK Daily Air Quality Index (DEFRA)
    https://uk-air.defra.gov.uk
    Official UK monitoring network with health advice bands.

These platforms also offer mobile apps, which are useful for checking conditions while travelling.


How to Interpret AQI in Practical Terms

AQI Category Practical Advice for Lung Conditions
0–50 Good Ideal conditions for outdoor activity
51–100 Moderate Usually safe; monitor symptoms
101–150 Unhealthy for sensitive groups Reduce strenuous outdoor activity; consider indoor plans
151–200 Unhealthy Limit time outdoors; avoid exertion
200+ Very Unhealthy/Hazardous Stay indoors with filtered air if possible

For many patients with CPA, ABPA or severe asthma, an AQI above 100 warrants caution. Above 150, limiting outdoor exposure is advisable.


Wildfire Smoke

Wildfire smoke contains high concentrations of PM2.5 and organic particulates. Even patients who are stable at home may experience:

  • Increased cough
  • Chest tightness
  • Increased sputum production
  • Fatigue

If travelling during wildfire season:

  • Check AQI daily
  • Plan indoor activities when levels are elevated
  • Use air-conditioned or filtered indoor environments
  • Carry rescue inhalers

Urban Pollution vs Rural Dust

Urban areas are more affected by traffic-related pollutants (NO₂, PM2.5), while rural or desert areas may present dust exposure. Both can aggravate inflamed airways.

The risk is cumulative. Short exposure is usually tolerated; prolonged high-level exposure increases the likelihood of symptom flare.


Key principle: checking AQI before and during travel is one of the simplest and most effective risk-reduction steps for people with chronic lung disease.


7. Heat, Humidity & Hydration Physiology

Hot climates place additional physiological stress on people with chronic lung disease.

Why Heat Matters

In warm environments, the body increases sweating and respiratory water loss to regulate temperature. This leads to:

  • Increased insensible fluid loss (fluid lost through breathing and skin)
  • Reduced plasma volume if intake is inadequate
  • Thickening of airway secretions

In bronchiectasis and chronic pulmonary aspergillosis (CPA), mucus clearance is already impaired. Dehydration increases mucus viscosity, making sputum:

  • Harder to expectorate
  • More likely to stagnate in damaged airways
  • Potentially more prone to secondary infection

Patients may notice thicker sputum, increased cough, or chest tightness in hot weather.


Humidity: Helpful or Harmful?

Humidity has mixed effects:

  • Moderate humidity can help prevent airway drying.
  • High humidity can increase environmental mould growth, particularly indoors if ventilation is poor.

In tropical or monsoon climates, poorly ventilated buildings may have higher fungal spore burdens due to damp conditions.


Heat, Fatigue & Breathlessness

Heat increases cardiovascular demand. The heart works harder to dissipate heat, which can:

  • Increase perceived breathlessness
  • Increase fatigue
  • Reduce exercise tolerance

This does not necessarily indicate worsening lung disease — but it can feel similar.


Hydration Strategy

Practical recommendations:

  • Begin hydrating the day before travel
  • Drink fluids regularly rather than waiting for thirst
  • Aim for pale straw-coloured urine
  • Increase intake during flights and hot excursions

Limit:

  • Excess alcohol (diuretic effect)
  • High caffeine intake

Additional Practical Measures

  • Plan outdoor activity early morning or evening
  • Rest during peak heat (midday)
  • Use air-conditioned environments when available
  • Continue airway clearance routines while travelling

Key principle: in chronic lung disease, hydration supports mucus clearance and reduces avoidable exacerbation risk during hot weather.


8. Travel Insurance & Full Medical Disclosure

Travel insurance is not a formality — it is a critical safety net for people with chronic lung disease.

When purchasing insurance, you must declare all pre-existing medical conditions. This typically includes:

  • Chronic Pulmonary Aspergillosis (CPA)
  • Allergic Bronchopulmonary Aspergillosis (ABPA)
  • Severe asthma
  • Bronchiectasis
  • Pulmonary fibrosis
  • Long-term steroid therapy
  • Adrenal insufficiency (if present)
  • Oxygen use (even if only occasional)

Why Full Disclosure Matters

If you fail to declare a relevant condition, the insurer may:

  • Refuse to cover medical treatment abroad
  • Decline repatriation costs
  • Refuse to reimburse cancelled flights or accommodation
  • Invalidate the entire policy

This applies even if the emergency appears unrelated. Insurers may review your full medical history during a claim.


What Insurers Typically Ask

You may be asked:

  • Have you been hospitalised in the past 12 months?
  • Have you had medication changes recently?
  • Have you had haemoptysis?
  • Are you awaiting tests or investigations?
  • Are you on long-term steroids?

Answer these questions carefully and honestly.


Policies and Stability

Some insurers will decline cover if:

  • You have been hospitalised recently
  • You are awaiting investigations
  • Your condition is considered unstable

This is another reason to travel during a period of clinical stability.


European Travel (UK Patients)

If travelling within Europe, ensure you carry:

  • Your GHIC (Global Health Insurance Card)

However, GHIC does not replace travel insurance. It may not cover:

  • Private healthcare
  • Mountain rescue
  • Repatriation to the UK

Practical Tips

  • Purchase insurance as soon as you book travel
  • Keep written confirmation of declared conditions
  • Carry the insurer’s emergency contact number with you
  • Inform the insurer early if you require hospital care abroad

In summary: full disclosure protects you. Insurance is only effective if the insurer understands your medical background from the outset.


9. Medication Planning & Contingency Prescriptions

  • Carry 1–2 weeks extra supply
  • Bring medications in original packaging
  • Carry clinic letter
  • Consider written rescue plan

10. Specific Considerations for Azole Antifungals

Azoles have significant drug–drug interactions.

  • Inform any clinician abroad you are taking an azole
  • Avoid grapefruit
  • Be aware of sun sensitivity (voriconazole)
  • Take itraconazole with food


11. Air Travel: What Actually Happens in the Cabin?

Commercial aircraft cabins are pressurised to simulate an altitude of approximately 6,000–8,000 feet (1,800–2,400 metres).

This means the partial pressure of oxygen is lower than at sea level. For healthy individuals this causes only a small drop in oxygen saturation (typically 3–4%).

Are Most People with Aspergillosis OK to Fly?

Yes — most stable patients fly without difficulty.

People who are:

  • Clinically stable
  • Not oxygen-dependent
  • Without recent haemoptysis
  • With resting oxygen saturations ≥95%

generally tolerate commercial flights well, including medium and long-haul travel.

Many patients report anxiety before their first flight after diagnosis, but in stable disease, significant problems are uncommon.


Who Should Consider Fit-to-Fly Testing?

Assessment may be appropriate if you have:

  • Resting oxygen saturation consistently below 95%
  • Advanced pulmonary fibrosis
  • Extensive cavitation
  • Significant breathlessness at minimal exertion
  • Recent clinical deterioration

The test commonly used is a Hypoxic Challenge Test (HCT), which simulates cabin oxygen conditions to determine whether supplemental oxygen is required during flight.

Where would I have a Hypoxic Challenge Test (HCT)?

In the UK, a Hypoxic Challenge Test is usually arranged through a hospital respiratory physiology department.

You cannot book this test directly. It must be requested by:

  • Your respiratory consultant or clinic, or
  • Occasionally your GP (who would refer you to a hospital service)

The test is typically performed in:

  • A hospital lung function laboratory
  • A respiratory physiology unit
  • A specialist respiratory centre

During the test, you breathe a gas mixture containing a lower oxygen concentration (usually around 15%) to simulate aircraft cabin conditions. Your oxygen saturation is monitored continuously. If levels fall below safe thresholds, in-flight oxygen may be recommended.

Do Most People Need This Test?

No. Many stable patients with normal resting oxygen saturation (typically ≥95%) do not require hypoxic challenge testing.

The test is generally considered if you:

  • Have resting oxygen saturation below 95%
  • Have advanced pulmonary fibrosis
  • Are already using oxygen
  • Have significant exertional desaturation

If you are unsure, ask your respiratory team whether assessment is appropriate for you.


Symptoms During Flight: What Is Normal?

Mild symptoms that can occur in stable patients include:

  • Slight increase in breathlessness on walking the aisle
  • Fatigue
  • Dry cough (often due to low humidity)

These are usually temporary and not dangerous.

Severe symptoms (marked breathlessness at rest, chest pain, dizziness, confusion) are uncommon and require crew notification.


Anxiety vs Physiological Breathlessness

It is very common for people with chronic lung disease to experience heightened awareness of their breathing during flights. The enclosed environment, reduced cabin pressure and awareness of altitude can all increase anxiety.

Anxiety-related breathlessness typically presents as:

  • A sensation of not getting a “satisfying” breath
  • Chest tightness without wheeze
  • Rapid breathing (hyperventilation)
  • Tingling in fingers or lips
  • Light-headedness

Hyperventilation lowers carbon dioxide levels in the blood. This can cause dizziness, tingling and a feeling of air hunger — even when oxygen levels are normal.

Physiological hypoxia (true low oxygen levels) is less common in stable patients who have been assessed as fit to fly. When it occurs, it is more likely in those with advanced fibrosis, low baseline oxygen saturations, or recent instability.

Features more suggestive of physiological compromise include:

  • Persistent breathlessness at rest
  • Worsening cyanosis (bluish lips or fingers)
  • Marked fatigue or confusion
  • Objective low oxygen saturation if measured

For patients who have undergone fit-to-fly assessment and been cleared to travel, significant in-flight hypoxia is uncommon.

Practical Strategies

  • Use slow, paced breathing (e.g. inhale for 4 seconds, exhale for 6 seconds)
  • Focus on extended exhalation to reduce hyperventilation
  • Keep shoulders relaxed and posture upright
  • Avoid repeatedly “checking” your breathing
  • Remind yourself that mild symptoms are common and expected

Understanding the difference between anxiety-related breathlessness and true hypoxia can significantly reduce distress during flight.


Deep Vein Thrombosis (DVT) Risk

Chronic lung disease does not automatically increase DVT risk, but long-haul immobility does.

General advice:

  • Move legs regularly
  • Stay hydrated
  • Avoid excess alcohol

12. Cabin Dryness & Post-Flight Airway Irritation

Cabin humidity is typically 10–20% (normal indoor comfort is 40–60%).

Low humidity can:

  • Dry airway lining
  • Reduce mucociliary clearance
  • Thicken secretions
  • Trigger cough or mild bronchospasm

This is often why people feel they have “caught a cold” the day after flying. In most cases, it is airway irritation rather than infection.

How to Reduce Dryness Effects

  • Hydrate well before and during flight
  • Limit alcohol and caffeine
  • Use isotonic saline nasal spray
  • Continue preventer inhalers
  • Keep rescue inhaler accessible
  • Avoid direct overhead air vents blowing onto your face
  • Consider mask use — masks increase humidity of inhaled air

Symptoms typically settle within 24–48 hours.


When to Seek Advice After Flying

Seek medical advice if you develop:

  • Progressively worsening breathlessness
  • Persistent fever
  • Significant haemoptysis
  • Chest pain

In stable patients, serious in-flight deterioration is uncommon.


12. Cabin Dryness & Post-Flight Irritation

Cabin humidity is 10–20%.

Dry air:

  • Reduces mucociliary clearance
  • Thickens secretions
  • Triggers cough
  • Irritates airways

Hydration and saline sprays reduce symptoms. Post-flight irritation commonly lasts 24–48 hours and does not necessarily indicate infection.


13. Travelling with Oxygen

Confirm airline device approval and battery duration. Plan well in advance.


14. Accommodation Risk Reduction

Request:

  • Hard flooring
  • No damp odour
  • No renovation dust
  • Pet-free rooms

Chains Often Reported as Allergy-Conscious

  • Hyatt
  • Hilton
  • Marriott
  • Scandic
  • Premier Inn

Newer business hotels often have better HVAC filtration.


15. High-Spore & Dust Exposure Environments

  • Compost handling
  • Construction sites
  • Flood-damaged buildings
  • Agricultural dust

Avoid heavy inhalation exposure.


16. Infection Prevention

  • Hand hygiene
  • Avoid close contact with visibly unwell individuals
  • Maintain vaccination schedule

17. Haemoptysis Planning

If you have a history of haemoptysis:

  • Know your previous pattern
  • Carry clinic contact details
  • Seek urgent care if volume increases significantly

18. Red Flag Symptoms

  • Increasing breathlessness
  • New or worsening haemoptysis
  • Persistent fever
  • Severe chest pain

19. Advanced Planning Checklist

  • Travel when stable
  • Plan with GP and respiratory clinic
  • Carry documentation
  • Monitor AQI
  • Hydrate on flights
  • Avoid damp & heavy dust
  • Know red flags

With preparation, most people with stable aspergillosis travel safely and successfully.